Skip to main content
. 2019 Jan 12;20:48–52. doi: 10.12659/AJCR.912115

Figure 1.

Figure 1.

Thoracic and abdominal contrast-enhanced computed tomography (CT) scans between November 2015 to September 2017 of a 61-year-old man with a chromophobe renal cell carcinoma treated with Rigvir®. (A) Thoracic contrast-enhanced computed tomography (CT) scan shows a subpleural nodule (13 November 2015). (B) Thoracic contrast-enhanced CT scan (20 June 2016). (C) Thoracic contrast-enhanced CT scan (21 September 2017). (D) Abdominal contrast-enhanced CT scan shows cysts in the liver parenchyma (13 November 2015). (E) Abdominal contrast-enhanced CT scan (20 June 2016). (F) Abdominal contrast-enhanced CT scan (21 September 2017). (G) Abdominal contrast-enhanced CT scan shows cysts in the liver parenchyma (13 November 2015). (H) Abdominal contrast-enhanced CT scan (20 June 2016). (I) Abdominal contrast-enhanced CT scan (21 September 2017).